For decades, the idea of “antioxidants for ageing” was dominated by familiar nutrients such as vitamins C and E. Now another compound is attracting considerable attention in longevity research —
ergothioneine.
It is found particularly abundantly in mushrooms, cannot be synthesised by the human body, and is actively taken up and retained by our tissues through a specialised transporter. That combination has led scientists to ask an intriguing question:
Could ergothioneine be a previously overlooked nutrient involved in healthy ageing?
Why scientists are interested
Ergothioneine is a naturally occurring sulphur-containing derivative of the amino acid histidine. It is produced primarily by fungi and certain microorganisms, while humans obtain it through food.
What makes it unusual is the way the body handles it.
We possess a highly selective transporter known as
OCTN1/SLC22A4, which absorbs ergothioneine and allows it to accumulate in a range of tissues. That is important because the body does not treat every dietary antioxidant this way.
Recent reviews describe particularly strong retention of ergothioneine in tissues exposed to substantial metabolic or oxidative stress, including the brain, liver, kidneys, eyes and blood cells.
This selective transport and retention is one reason ergothioneine has been proposed as a possible
“longevity vitamin.”
The 2026 longevity discussion
Interest accelerated further at the
Unlock Healthy Longevity Conference in Singapore in February 2026. The programme devoted a substantial section specifically to ergothioneine, including Professor Barry Halliwell presenting recent developments and Professor Robert Beelman asking whether ergothioneine could be a “longevity vitamin” capable of contributing to healthy ageing.
Ergothioneine is often described simply as an antioxidant, but that probably understates what makes it interesting. Its chemistry makes it unusually stable, while its transporter allows it to be actively concentrated inside the body.
Research increasingly points towards broader
cytoprotective effects, including interactions with oxidative stress, inflammatory signalling, cellular metabolism and mitochondrial function. One particularly important question has been whether ergothioneine can actually reach mitochondria.
In 2024 researchers demonstrated direct ergothioneine uptake into isolated mitochondria and detected it within mitochondria obtained from treated cells and animals.
Interestingly, mitochondrial uptake was reduced but not completely abolished when OCTN1 was absent, raising the possibility that additional mitochondrial transport mechanisms may exist.
That gives scientists a plausible mechanism through which ergothioneine could help protect mitochondrial structures from oxidative injury.
But we should be careful here. Mitochondrial protection demonstrated experimentally does
not yet mean that taking ergothioneine supplements has been proven to slow human ageing.
Ergothioneine and the ageing brain
The neurological evidence may ultimately prove to be one of the most interesting aspects of ergothioneine research. Lower circulating ergothioneine has been associated in observational studies with ageing and with several age-related disorders, particularly cognitive decline and neurodegenerative disease.
A major review published in August 2026 concluded that the growing evidence is particularly suggestive in relation to neurodegenerative ageing — while also emphasising how much fundamental research remains to be done.
More importantly, a small randomised controlled pilot trial has now tested ergothioneine directly.
Researchers recruited
19 adults aged 60 or over with mild cognitive impairment. Participants received either placebo or
25 mg ergothioneine three times each week for one year.
Those taking ergothioneine showed improvement in a measure of verbal learning and maintained relatively stable levels of
neurofilament light chain, a biomarker associated with neuronal damage. In the placebo group, neurofilament light increased during the study. No significant adverse changes were detected in routine blood, kidney or liver safety markers.
These findings are intriguing. But nineteen participants are nowhere near enough to demonstrate that ergothioneine prevents dementia or substantially alters brain ageing. The trial should be regarded as an
early clinical signal requiring confirmation in much larger studies.
Where do we get ergothioneine?
This is perhaps the most appealing part of the story. Ergothioneine is a dietary compound rather than a synthetic longevity drug. Its richest commonly consumed sources are
mushrooms.
Different species contain very different amounts, and concentrations are influenced by fungal species, growing conditions, substrate and cultivation techniques.
Porcini and several members of the
Pleurotus — oyster mushroom — family are among the particularly interesting sources, while shiitake and other culinary mushrooms can also contribute meaningful amounts.
This raises an important question for nutritional longevity research:
Could regular mushroom consumption help maintain ergothioneine status as we age?
At present we do not know exactly how much ergothioneine humans require — or even whether a formal requirement will eventually be established. But dietary exposure may prove to be considerably more relevant than previously recognised.
Why this matters for longevity medicine
The ergothioneine story illustrates an important change taking place in ageing research.
Rather than trying simply to “eliminate free radicals,” researchers are increasingly studying how particular molecules interact with:
- mitochondrial resilience,
- cellular stress responses,
- inflammatory signalling,
- neurological ageing,
- metabolic regulation,
- and the body's own protective systems.
Ergothioneine may eventually prove to be part of that network. For now, it deserves neither dismissal nor miracle-status. What we have is something considerably more interesting:
a food-derived molecule that humans cannot manufacture, that our bodies possess a specialised system to retain, that accumulates in vulnerable tissues, and that is beginning to show intriguing signals in human ageing research.
Whether it ultimately deserves to be called a
“longevity vitamin” remains to be discovered.
Wildberry Research View
Ergothioneine is not yet an established anti-ageing therapy. The strongest current rationale lies in its unusual physiology, mitochondrial and cytoprotective mechanisms, epidemiological associations and emerging early human data.
For the moment, a
food-first approach incorporating ergothioneine-rich mushrooms is considerably easier to justify than high-dose supplementation. The next generation of clinical trials should tell us whether ergothioneine is simply another beneficial dietary compound — or whether it represents something more fundamental in human healthy ageing.
Selected references
Halliwell B. et al. Ergothioneine research and physiology.
Cheah IK et al. Ergothioneine and mitochondrial uptake.
Feng L et al. Investigation of ergothioneine in mild cognitive impairment: randomised placebo-controlled pilot study.
Zheng J et al. Ergothioneine: An updated review on preparation strategies, biological activity and mechanisms, health and functional applications. Food Chemistry. 2026.
Ergothioneine as an Emerging Food-Derived Bioactive Compound Protecting against Age-related Diseases: Issues Needing More Research. American Journal of Clinical Nutrition. 2026.
Unlock Healthy Longevity Conference, Singapore, February 2026.
Disclaimer: This article is for educational purposes and does not constitute medical advice. Evidence concerning ergothioneine supplementation and healthy ageing remains preliminary, and larger clinical trials are required before therapeutic recommendations can be made.
